Vasilisa Udalova
Vasilisa Udalova has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Ilya V. Kanivets
Genomed LLC, Moscow, Russia
7 shared publications - Aysylu Murtazina
Research Centre for Medical Genetics
4 shared publications - Elena Leonidovna Dadali
Research Centre for Medical Genetics
4 shared publications - Oksana P. Ryzhkova
Research Centre for Medical Genetics, Moskvorechye st., 1, 115522 Moscow, Russia
4 shared publications - Artem Borovikov
Research Centre for Medical Genetics Moscow Russia
3 shared publications - Galina E. Rudenskaya
Research Centre for Medical Genetics
3 shared publications
Latest Publications
- 20 August 2026
- Published by Pleiades Publishing Ltd in Cell and Tissue Biology
- Vol. 20 (S2) , S178-S189
Prenatal Whole-exome Sequencing in a Russian Clinical Cohort: Diagnostic Yield, Indications, and Spectrum of Molecular Findings
Objective: Prenatal whole-exome sequencing (prWES) is a promising molecular diagnostic tool that can be used to clarify the genetic etiology of prenatally detected abnormalities, including cases in which standard genetic testing fails to establish their cause. However, data on its diagnostic yield and the spectrum of detectable abnormalities in Russian clinical practice remain limited. Objective: To perform a retrospective analysis of the indications for prWES, its diagnostic yield, and the spectrum of molecular findings in a Russian clinical cohort. Materials and methods: This retrospective cohort study included 485 pregnancies in which prWES was performed. Results: The most common indications for testing were fetal structural anomalies (43.71%), ultrasound markers of chromosomal abnormalities (24.74%), and adverse family history (21.65%). Pathogenic and likely pathogenic variants were identified in 73 of 485 cases (15.05%), variants of uncertain significance in 104 cases (21.24%), and secondary findings in 3 cases (0.62%). The highest diagnostic yield was observed in fetuses with structural anomalies, in whom pathogenic and likely pathogenic variants were detected in 17.92% of cases. In the group with ultrasound markers of chromosomal abnormalities, the diagnostic yield was 12.5%, whereas in cases with adverse family history it was 11.43%. Among the confirmed molecular disorders, skeletal dysplasias and connective tissue disorders (27.4%), Noonan syndrome and Noonan-related disorders (19.18%), and neurodevelopmental disorders (17.81%) predominated. Conclusion: prWES demonstrates high clinical utility in the diagnosis of fetal monogenic disorders and shows the greatest effectiveness in fetuses with structural anomalies and in families at high genetic risk. These findings may contribute to the optimization of prenatal diagnostic algorithms and genetic counseling strategies.
- 20 August 2026
- Published by Pleiades Publishing Ltd in Cell and Tissue Biology
- Vol. 20 (S2) , S178-S189
Prenatal Whole-exome Sequencing in a Russian Clinical Cohort: Diagnostic Yield, Indications, and Spectrum of Molecular Findings
Objective: Prenatal whole-exome sequencing (prWES) is a promising molecular diagnostic tool that can be used to clarify the genetic etiology of prenatally detected abnormalities, including cases in which standard genetic testing fails to establish their cause. However, data on its diagnostic yield and the spectrum of detectable abnormalities in Russian clinical practice remain limited. Objective: To perform a retrospective analysis of the indications for prWES, its diagnostic yield, and the spectrum of molecular findings in a Russian clinical cohort. Materials and methods: This retrospective cohort study included 485 pregnancies in which prWES was performed. Results: The most common indications for testing were fetal structural anomalies (43.71%), ultrasound markers of chromosomal abnormalities (24.74%), and adverse family history (21.65%). Pathogenic and likely pathogenic variants were identified in 73 of 485 cases (15.05%), variants of uncertain significance in 104 cases (21.24%), and secondary findings in 3 cases (0.62%). The highest diagnostic yield was observed in fetuses with structural anomalies, in whom pathogenic and likely pathogenic variants were detected in 17.92% of cases. In the group with ultrasound markers of chromosomal abnormalities, the diagnostic yield was 12.5%, whereas in cases with adverse family history it was 11.43%. Among the confirmed molecular disorders, skeletal dysplasias and connective tissue disorders (27.4%), Noonan syndrome and Noonan-related disorders (19.18%), and neurodevelopmental disorders (17.81%) predominated. Conclusion: prWES demonstrates high clinical utility in the diagnosis of fetal monogenic disorders and shows the greatest effectiveness in fetuses with structural anomalies and in families at high genetic risk. These findings may contribute to the optimization of prenatal diagnostic algorithms and genetic counseling strategies.
- 9 December 2025
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 22 (3) , 180-195
Genomic imprinting disorders in the structure of syndromic obesity in children
BACKGROUND . Genomic imprinting disorders represent a distinct class of hereditary diseases caused by disruption of the monoallelic expression of imprinted genes. Several of them are closely associated with obesity and metabolic disturbances. Syndromes such as Prader–Willi, Angelman, Schaaf–Yang, Temple, and pseudohypoparathyroidism types 1a and 1b illustrate how dysregulation of imprinted gene expression can lead to energy imbalance, hyperphagia, reduced physical activity, and abnormal fat distribution. Currently, the proportion of early-onset and severe obesity cases caused by genetic factors is steadily increasing. AIM . To study the clinical and genetic characteristics of syndromic forms of obesity in children. MATERIALS AND METHODS . A retrospective non-comparative study. The study included 186 patients who were examined at the Endocrinology Research Center with suspected genetic forms of obesity in the period from October 2022 to May 2025. RESULTS . Genomic imprinting disorders were confirmed in 12% of patients (n=22), including: Prader–Willi syndrome (n=12), Angelman syndrome (n=1), Schaaf–Yang syndrome (n=1), Temple syndrome (n=1), multilocus imprinting disturbances (MLID) (n=1), and pseudohypoparathyroidism type 1a (n=6). At the time of examination: 13.6% (n=3) had overweight (BMI SDS 1.0–1.9 SD), 4.6% (n=1) had grade 1 obesity (BMI SDS 2.0–2.4 SD), 18.2% (n=4) had grade 3 obesity (BMI SDS 3.0–3.9 SD), and 40.9% (n=9) had morbid obesity (BMI SDS≥4.0 SD). Excessive weight gain during the first year of life was observed in 40.9% (n=9), and in 31.8% (n=7) starting from the second year of life. Clinical signs of hyperphagia were identified in 54.5% of cases (n=12). A positive family history of obesity was identified in 31.8% of cases (n=7). The median BMI SDS was 3.71 SD [1.8025; 4.2875]. Obesity- and overweight-related complications were observed in 13 out of 17 patients. CONCLUSION . The study presents the genetic and clinical characteristics of genomic imprinting disorders within the structure of syndromic obesity in children in the Russian Federation.
- 9 December 2025
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 22 (3) , 180-195
Genomic imprinting disorders in the structure of syndromic obesity in children
BACKGROUND . Genomic imprinting disorders represent a distinct class of hereditary diseases caused by disruption of the monoallelic expression of imprinted genes. Several of them are closely associated with obesity and metabolic disturbances. Syndromes such as Prader–Willi, Angelman, Schaaf–Yang, Temple, and pseudohypoparathyroidism types 1a and 1b illustrate how dysregulation of imprinted gene expression can lead to energy imbalance, hyperphagia, reduced physical activity, and abnormal fat distribution. Currently, the proportion of early-onset and severe obesity cases caused by genetic factors is steadily increasing. AIM . To study the clinical and genetic characteristics of syndromic forms of obesity in children. MATERIALS AND METHODS . A retrospective non-comparative study. The study included 186 patients who were examined at the Endocrinology Research Center with suspected genetic forms of obesity in the period from October 2022 to May 2025. RESULTS . Genomic imprinting disorders were confirmed in 12% of patients (n=22), including: Prader–Willi syndrome (n=12), Angelman syndrome (n=1), Schaaf–Yang syndrome (n=1), Temple syndrome (n=1), multilocus imprinting disturbances (MLID) (n=1), and pseudohypoparathyroidism type 1a (n=6). At the time of examination: 13.6% (n=3) had overweight (BMI SDS 1.0–1.9 SD), 4.6% (n=1) had grade 1 obesity (BMI SDS 2.0–2.4 SD), 18.2% (n=4) had grade 3 obesity (BMI SDS 3.0–3.9 SD), and 40.9% (n=9) had morbid obesity (BMI SDS≥4.0 SD). Excessive weight gain during the first year of life was observed in 40.9% (n=9), and in 31.8% (n=7) starting from the second year of life. Clinical signs of hyperphagia were identified in 54.5% of cases (n=12). A positive family history of obesity was identified in 31.8% of cases (n=7). The median BMI SDS was 3.71 SD [1.8025; 4.2875]. Obesity- and overweight-related complications were observed in 13 out of 17 patients. CONCLUSION . The study presents the genetic and clinical characteristics of genomic imprinting disorders within the structure of syndromic obesity in children in the Russian Federation.
- Open Access
- 2 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8521
Clinical and Molecular Presentation of a Patient with Paternal Uniparental Isodisomy of Chromosome 16
Uniparental disomies (UPDs) are among the causes of imprinting disorders. Specific phenotypes of most causative UPDs have been described. Here, we describe the case of a 2-year-old female patient who presented a syndromic phenotype. Chromosomal microarray analysis revealed UPD of the whole chromosome 16. Microsatellite analysis demonstrated paternal origin of the UPD and its isodisomic pattern (UPiD (16) pat). Mosaic trisomy 16 was not detected using the FISH method. Whole-exome sequencing revealed no pathogenetic genetic variants sufficient to explain the syndromic phenotype nor unmasked pathogenic recessive genetic variants on chromosome 16. Whole-genome trio DNA sequencing revealed no additional candidate pathogenic genetic variants to those detected by whole-exome sequencing, including miRNAs and lncRNAs. Imprinting disorders at 6q24.2, 7p12.2, 7q32.2, 11p15.5, 14q32.2, 15q11.2, and 20q13.32, as well as multilocus imprinting disturbances (MLIDs), were excluded by Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA). At the same time, we detected abnormal hypermethylation of the ZNF597 transcription start site differentially methylated region (ZNF597:TSS-DMR), accompanied by hypomethylation of the neighbouring ZNF597:3′ DMR. Both DMRs were normally imprinted, and the DNA alterations in our patient with UPD (16) pat are opposite to those previously described for maternal uniparental disomy (UPD (16) mat). To date, several cases of UPD (16) pat have been reported. Our case report describes the syndromic phenotype of a patient with paternal uniparental disomy of chromosome 16 in contrast to the previously described patients with a normal phenotype or with abnormal phenotypes caused by acquired homozygosity of pathogenic variants at autosomal recessive genes located on this chromosome. Reporting such observations will help systematize data on the phenotypes of imprinting disorders on chromosome 16.
- 2 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8521
Open AccessClinical and Molecular Presentation of a Patient with Paternal Uniparental Isodisomy of Chromosome 16
Uniparental disomies (UPDs) are among the causes of imprinting disorders. Specific phenotypes of most causative UPDs have been described. Here, we describe the case of a 2-year-old female patient who presented a syndromic phenotype. Chromosomal microarray analysis revealed UPD of the whole chromosome 16. Microsatellite analysis demonstrated paternal origin of the UPD and its isodisomic pattern (UPiD (16) pat). Mosaic trisomy 16 was not detected using the FISH method. Whole-exome sequencing revealed no pathogenetic genetic variants sufficient to explain the syndromic phenotype nor unmasked pathogenic recessive genetic variants on chromosome 16. Whole-genome trio DNA sequencing revealed no additional candidate pathogenic genetic variants to those detected by whole-exome sequencing, including miRNAs and lncRNAs. Imprinting disorders at 6q24.2, 7p12.2, 7q32.2, 11p15.5, 14q32.2, 15q11.2, and 20q13.32, as well as multilocus imprinting disturbances (MLIDs), were excluded by Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA). At the same time, we detected abnormal hypermethylation of the ZNF597 transcription start site differentially methylated region (ZNF597:TSS-DMR), accompanied by hypomethylation of the neighbouring ZNF597:3′ DMR. Both DMRs were normally imprinted, and the DNA alterations in our patient with UPD (16) pat are opposite to those previously described for maternal uniparental disomy (UPD (16) mat). To date, several cases of UPD (16) pat have been reported. Our case report describes the syndromic phenotype of a patient with paternal uniparental disomy of chromosome 16 in contrast to the previously described patients with a normal phenotype or with abnormal phenotypes caused by acquired homozygosity of pathogenic variants at autosomal recessive genes located on this chromosome. Reporting such observations will help systematize data on the phenotypes of imprinting disorders on chromosome 16.
- Open Access
- 31 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1257
A Spectrum of Pathogenic Variants in the LAMA2 Gene in the Russian Federation
LAMA2-associated muscular dystrophy is a rare genetic disorder caused by pathogenic or likely pathogenic variants in the LAMA2 gene. The aim of this study is to characterize the spectrum of pathogenic/likely pathogenic variants in the LAMA2 gene among Russian patients, identify frequent pathogenic variants specific to this population, and estimate the prevalence of this disorder in Russia. Data were collected and analyzed from patients with confirmed diagnoses of LAMA2-associated muscular dystrophy using various molecular genetic methods in research centers from 2008 to 2024. Data were obtained from 90 unrelated patients with LAMA2-associated muscular dystrophy, out of which 83 presented with the more severe form, MDC1A1, while seven had milder form of LAMA2-associated muscular dystrophy. The most common pathogenic variants identified were nonsense mutations (40% of cases), followed by frameshift variants (29.3%), splicing variants (21.4%), gross deletions (5.3%), and missense variants (4%). It is worth noting that missense variants were found exclusively in patients with the milder form of LAMA2-associated muscular dystrophy. The most prevalent identified pathogenic variant was c.7536del (15%), characteristic of Slavic populations with an established founder effect. Additionally, a common pathogenic variant, c.8245-2A>G, was found predominantly in Kazan Tatars. The estimated prevalence of LAMA2-associated muscular dystrophy in Russia is approximately 1 in 117,700.
- 31 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1257
Open AccessA Spectrum of Pathogenic Variants in the LAMA2 Gene in the Russian Federation
LAMA2-associated muscular dystrophy is a rare genetic disorder caused by pathogenic or likely pathogenic variants in the LAMA2 gene. The aim of this study is to characterize the spectrum of pathogenic/likely pathogenic variants in the LAMA2 gene among Russian patients, identify frequent pathogenic variants specific to this population, and estimate the prevalence of this disorder in Russia. Data were collected and analyzed from patients with confirmed diagnoses of LAMA2-associated muscular dystrophy using various molecular genetic methods in research centers from 2008 to 2024. Data were obtained from 90 unrelated patients with LAMA2-associated muscular dystrophy, out of which 83 presented with the more severe form, MDC1A1, while seven had milder form of LAMA2-associated muscular dystrophy. The most common pathogenic variants identified were nonsense mutations (40% of cases), followed by frameshift variants (29.3%), splicing variants (21.4%), gross deletions (5.3%), and missense variants (4%). It is worth noting that missense variants were found exclusively in patients with the milder form of LAMA2-associated muscular dystrophy. The most prevalent identified pathogenic variant was c.7536del (15%), characteristic of Slavic populations with an established founder effect. Additionally, a common pathogenic variant, c.8245-2A>G, was found predominantly in Kazan Tatars. The estimated prevalence of LAMA2-associated muscular dystrophy in Russia is approximately 1 in 117,700.
- Open Access
- 12 February 2024
- Published by Wiley in Human Mutation
- Vol. 2024, 1-13
The Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study
This study is aimed at investigating the clinical and genetic characteristics of 244 unrelated probands diagnosed with multiple osteochondromas (MO). The diagnosis of MO typically involves identifying multiple benign bone tumors known as osteochondromas (OCs) through imaging studies and physical examinations. However, cases with both OCs and enchondromas (ECs) may indicate the more rare condition metachondromatosis (MC), which is assumed to be distinct disease. Previous cohort studies of MO found heterozygous loss-of-function (LoF) variants only in the EXT1 or EXT2 genes, with DNA diagnostic yield ranging from 78 to 95. The PTPN11 gene, which is causative for MC, was not previously investigated as a gene candidate for MO. In this study, we detected a total of 177 unique single nucleotide and copy number variants in three genes across 220 probands, consisting of 80 previously reported and 97 novel variants. Specifically, we identified five cases with OCs and no ECs as well as four cases with MC carrying LoF variants in the PTPN11 gene and two additional cases with ECs harboring variants in the EXT1/2 genes. These findings suggest a potential overlap between the MO and MC both phenotypically and genetically. These findings highlight the importance of expanding genetic testing beyond the EXT1 and EXT2 genes in MO cases, as other genes such as PTPN11 may also be causative. This can improve the accuracy of diagnosis and treatment for individuals with MO and MC. It is essential to determine whether MO and MC represent distinct diseases or if they encompass a broader clinical spectrum.
- 12 February 2024
- Published by Wiley in Human Mutation
- Vol. 2024, 1-13
Open AccessThe Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study
This study is aimed at investigating the clinical and genetic characteristics of 244 unrelated probands diagnosed with multiple osteochondromas (MO). The diagnosis of MO typically involves identifying multiple benign bone tumors known as osteochondromas (OCs) through imaging studies and physical examinations. However, cases with both OCs and enchondromas (ECs) may indicate the more rare condition metachondromatosis (MC), which is assumed to be distinct disease. Previous cohort studies of MO found heterozygous loss-of-function (LoF) variants only in the EXT1 or EXT2 genes, with DNA diagnostic yield ranging from 78 to 95. The PTPN11 gene, which is causative for MC, was not previously investigated as a gene candidate for MO. In this study, we detected a total of 177 unique single nucleotide and copy number variants in three genes across 220 probands, consisting of 80 previously reported and 97 novel variants. Specifically, we identified five cases with OCs and no ECs as well as four cases with MC carrying LoF variants in the PTPN11 gene and two additional cases with ECs harboring variants in the EXT1/2 genes. These findings suggest a potential overlap between the MO and MC both phenotypically and genetically. These findings highlight the importance of expanding genetic testing beyond the EXT1 and EXT2 genes in MO cases, as other genes such as PTPN11 may also be causative. This can improve the accuracy of diagnosis and treatment for individuals with MO and MC. It is essential to determine whether MO and MC represent distinct diseases or if they encompass a broader clinical spectrum.
- Open Access
- 14 October 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (10) , 1492
Pediatric Patients with Sitosterolemia: Next-Generation Sequencing and Biochemical Examination in Clinical Practice
Here, we report the pediatric cases of sitosterolemia, a rare autosomal-recessive genetic disorder, characterized by high concentrations of plant sterols in blood and heterogeneity manifestations. All three patients (two girls aged 2 and 6 years old, and one boy aged 14 years old) were initially diagnosed with hypercholesterinemia. Next-generation sequencing (NGS) revealed homozygous (p.Leu572Pro/p.Leu572Pro) and compound (p.Leu572Pro/p.Gly512Arg and p.Leu572Pro/p.Trp361*) variants in the ABCG8 gene that allowed for the diagnosis of sitosterolemia. Two patients whose blood phytosterol levels were estimated before the diet demonstrated high levels of sitosterol/campesterol (69.6/29.2 and 28.3/12.4 μmol/L, respectively). Here, we demonstrate that NGS-testing led to the proper diagnosis that is essential for patients’ management. The variant p.Leu572Pro might be prevalent among patients with sitosterolemia in Russia.
- 14 October 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (10) , 1492
Open AccessPediatric Patients with Sitosterolemia: Next-Generation Sequencing and Biochemical Examination in Clinical Practice
Here, we report the pediatric cases of sitosterolemia, a rare autosomal-recessive genetic disorder, characterized by high concentrations of plant sterols in blood and heterogeneity manifestations. All three patients (two girls aged 2 and 6 years old, and one boy aged 14 years old) were initially diagnosed with hypercholesterinemia. Next-generation sequencing (NGS) revealed homozygous (p.Leu572Pro/p.Leu572Pro) and compound (p.Leu572Pro/p.Gly512Arg and p.Leu572Pro/p.Trp361*) variants in the ABCG8 gene that allowed for the diagnosis of sitosterolemia. Two patients whose blood phytosterol levels were estimated before the diet demonstrated high levels of sitosterol/campesterol (69.6/29.2 and 28.3/12.4 μmol/L, respectively). Here, we demonstrate that NGS-testing led to the proper diagnosis that is essential for patients’ management. The variant p.Leu572Pro might be prevalent among patients with sitosterolemia in Russia.
- Open Access
Genetic and Clinical Spectrum of GNE Myopathy in Russia
GNE myopathy (GNEM) is a rare hereditary disease, but at the same time, it is the most common distal myopathy in several countries due to a founder effect of some pathogenic variants in the GNE gene. We collected the largest cohort of patients with GNEM from Russia and analyzed their mutational spectrum and clinical data. In our cohort, 10 novel variants were found, including 2 frameshift variants and 2 large deletions. One novel missense variant c.169_170delGCinsTT (p.(Ala57Phe)) was detected in 4 families in a homozygous state and in 3 unrelated patients in a compound heterozygous state. It was the second most frequent variant in our cohort. All families with this novel frequent variant were non-consanguineous and originated from the 3 neighboring areas in the European part of Russia. The clinical picture of the patients carrying this novel variant was typical, but the severity of clinical manifestation differed significantly. In our study, we reported two atypical cases expanding the phenotypic spectrum of GNEM. One female patient had severe quadriceps atrophy, hand joint contractures, keloid scars, and non-classical pattern on leg muscle magnetic resonance imaging, which was more similar to atypical collagenopathy rather than GNEM. Another patient initially had been observed with spinal muscular atrophy due to asymmetric atrophy of hand muscles and results of electromyography. The peculiar pattern of muscle involvement on magnetic resonance imaging consisted of pronounced changes in the posterior thigh muscle group with relatively spared muscles of the lower legs, apart from the soleus muscles. Different variants in the GNE gene were found in both atypical cases. Thus, our data expand the mutational and clinical spectrum of GNEM.
Open AccessGenetic and Clinical Spectrum of GNE Myopathy in Russia
GNE myopathy (GNEM) is a rare hereditary disease, but at the same time, it is the most common distal myopathy in several countries due to a founder effect of some pathogenic variants in the GNE gene. We collected the largest cohort of patients with GNEM from Russia and analyzed their mutational spectrum and clinical data. In our cohort, 10 novel variants were found, including 2 frameshift variants and 2 large deletions. One novel missense variant c.169_170delGCinsTT (p.(Ala57Phe)) was detected in 4 families in a homozygous state and in 3 unrelated patients in a compound heterozygous state. It was the second most frequent variant in our cohort. All families with this novel frequent variant were non-consanguineous and originated from the 3 neighboring areas in the European part of Russia. The clinical picture of the patients carrying this novel variant was typical, but the severity of clinical manifestation differed significantly. In our study, we reported two atypical cases expanding the phenotypic spectrum of GNEM. One female patient had severe quadriceps atrophy, hand joint contractures, keloid scars, and non-classical pattern on leg muscle magnetic resonance imaging, which was more similar to atypical collagenopathy rather than GNEM. Another patient initially had been observed with spinal muscular atrophy due to asymmetric atrophy of hand muscles and results of electromyography. The peculiar pattern of muscle involvement on magnetic resonance imaging consisted of pronounced changes in the posterior thigh muscle group with relatively spared muscles of the lower legs, apart from the soleus muscles. Different variants in the GNE gene were found in both atypical cases. Thus, our data expand the mutational and clinical spectrum of GNEM.
- Open Access
- 13 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (18) , 10606
Case Report: Compound Heterozygous Variants of the MAN1B1 Gene in a Russian Patient with Rafiq Syndrome
Rafiq syndrome (RAFQS) is a congenital disorder of glycosylation (CDG) that is caused by mutations in the MAN1B1 gene and characterized by impaired protein and lipid glycosylation. RAFQS is characterized by a delay in intellectual and motor development, facial and other dysmorphism, truncal obesity, behavior problems, and hypotonia. We describe a Russian patient with delayed intellectual and motor development, a lack of speech, disorientation in space and time, impaired attention and memory, and episodes of aggression. Screening for lysosomal, amino acid, organic acid, and mitochondrial disorders was normal. The patient was referred for the targeted sequencing of the “Hereditary Metabolic Disorders” panel. The genetic testing revealed two heterozygous pathogenic variants in the MAN1B1 gene: the previously reported c.1000C > T (p.Arg334Cys) and the novel c.1065 + 1 G > C. Thus, the patient’s clinical picture and genetic analysis confirmed RAFQS in the patient.
- 13 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (18) , 10606
Open AccessCase Report: Compound Heterozygous Variants of the MAN1B1 Gene in a Russian Patient with Rafiq Syndrome
Rafiq syndrome (RAFQS) is a congenital disorder of glycosylation (CDG) that is caused by mutations in the MAN1B1 gene and characterized by impaired protein and lipid glycosylation. RAFQS is characterized by a delay in intellectual and motor development, facial and other dysmorphism, truncal obesity, behavior problems, and hypotonia. We describe a Russian patient with delayed intellectual and motor development, a lack of speech, disorientation in space and time, impaired attention and memory, and episodes of aggression. Screening for lysosomal, amino acid, organic acid, and mitochondrial disorders was normal. The patient was referred for the targeted sequencing of the “Hereditary Metabolic Disorders” panel. The genetic testing revealed two heterozygous pathogenic variants in the MAN1B1 gene: the previously reported c.1000C > T (p.Arg334Cys) and the novel c.1065 + 1 G > C. Thus, the patient’s clinical picture and genetic analysis confirmed RAFQS in the patient.